Bepridil is effective and improves QOL in multidrug-resistant paroxysmal atrial fibrillation

Atsushi Shamoto, Akiko Chishaki, Miyuki Tsuchihashi-Makaya, Hiroaki Chishaki, Masao Takemoto, Yasushi Mukai, Shujiro Inoue, Kenji Sunagawa

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

OBJECTIVE: Efficacy and safety of long-term administration of bepridil as a rhythm and rate controller were comprehensively evaluated in patients with multidrug-resistant paroxysmal atrial fibrillation (PAF). METHODS: A retrospective survey from 1992 to 2006 was conducted on 62 multidrug-resistant PAF patients treated with bepridil from 480 consecutive PAF patients. In addition, a 5-year follow-up study was conducted on 28 of the 62 patients, being continued from 2006 to 2011. The efficacy of bepridil, improvement in symptoms including patients' quality of life (QOL), ECGs, hemodynamics, and its adverse effects were examined. RESULTS: In the retrospective survey, 127±44mg of bepridil was given for 21±18 months and 40.3% maintained sinus rhythm. Reductions in the frequency and the duration of each episode of PAF and improvement in symptoms were seen in 48.4, 50.0 and 93.5% of the 62 patients, respectively. Reversible torsades de pointes (TdP) occurred in two aged women. Bradycardia and hepatic dysfunction developed in one patient each. In the follow-up study, 100±20mg of bepridil was given. Sinus rhythm was maintained in 13 patients. Although the occurrences of PAF continued in 14 patients, their symptoms and QOL were improved. No adverse effects were noted in all 28 patients of the follow-up study. CONCLUSIONS: Bepridil was effective in rhythm control in 40% of PAF patients resistant to other antiarrhythmics. Even in those who had failed to maintain sinus rhythm, continued administration of low-dose bepridil improved their symptoms and QOL with few adverse effects. Bepridil is worth returning to use.

Original languageEnglish
Pages (from-to)747-754
Number of pages8
JournalJournal of Cardiovascular Medicine
Volume13
Issue number11
DOIs
Publication statusPublished - Nov 2012

Fingerprint

Bepridil
Atrial Fibrillation
Quality of Life
Torsades de Pointes
Bradycardia

All Science Journal Classification (ASJC) codes

  • Cardiology and Cardiovascular Medicine

Cite this

Bepridil is effective and improves QOL in multidrug-resistant paroxysmal atrial fibrillation. / Shamoto, Atsushi; Chishaki, Akiko; Tsuchihashi-Makaya, Miyuki; Chishaki, Hiroaki; Takemoto, Masao; Mukai, Yasushi; Inoue, Shujiro; Sunagawa, Kenji.

In: Journal of Cardiovascular Medicine, Vol. 13, No. 11, 11.2012, p. 747-754.

Research output: Contribution to journalArticle

Shamoto, A, Chishaki, A, Tsuchihashi-Makaya, M, Chishaki, H, Takemoto, M, Mukai, Y, Inoue, S & Sunagawa, K 2012, 'Bepridil is effective and improves QOL in multidrug-resistant paroxysmal atrial fibrillation', Journal of Cardiovascular Medicine, vol. 13, no. 11, pp. 747-754. https://doi.org/10.2459/JCM.0b013e3283585383
Shamoto, Atsushi ; Chishaki, Akiko ; Tsuchihashi-Makaya, Miyuki ; Chishaki, Hiroaki ; Takemoto, Masao ; Mukai, Yasushi ; Inoue, Shujiro ; Sunagawa, Kenji. / Bepridil is effective and improves QOL in multidrug-resistant paroxysmal atrial fibrillation. In: Journal of Cardiovascular Medicine. 2012 ; Vol. 13, No. 11. pp. 747-754.
@article{cb417c3bcb484c2c833fdb7d4d3d73b6,
title = "Bepridil is effective and improves QOL in multidrug-resistant paroxysmal atrial fibrillation",
abstract = "OBJECTIVE: Efficacy and safety of long-term administration of bepridil as a rhythm and rate controller were comprehensively evaluated in patients with multidrug-resistant paroxysmal atrial fibrillation (PAF). METHODS: A retrospective survey from 1992 to 2006 was conducted on 62 multidrug-resistant PAF patients treated with bepridil from 480 consecutive PAF patients. In addition, a 5-year follow-up study was conducted on 28 of the 62 patients, being continued from 2006 to 2011. The efficacy of bepridil, improvement in symptoms including patients' quality of life (QOL), ECGs, hemodynamics, and its adverse effects were examined. RESULTS: In the retrospective survey, 127±44mg of bepridil was given for 21±18 months and 40.3{\%} maintained sinus rhythm. Reductions in the frequency and the duration of each episode of PAF and improvement in symptoms were seen in 48.4, 50.0 and 93.5{\%} of the 62 patients, respectively. Reversible torsades de pointes (TdP) occurred in two aged women. Bradycardia and hepatic dysfunction developed in one patient each. In the follow-up study, 100±20mg of bepridil was given. Sinus rhythm was maintained in 13 patients. Although the occurrences of PAF continued in 14 patients, their symptoms and QOL were improved. No adverse effects were noted in all 28 patients of the follow-up study. CONCLUSIONS: Bepridil was effective in rhythm control in 40{\%} of PAF patients resistant to other antiarrhythmics. Even in those who had failed to maintain sinus rhythm, continued administration of low-dose bepridil improved their symptoms and QOL with few adverse effects. Bepridil is worth returning to use.",
author = "Atsushi Shamoto and Akiko Chishaki and Miyuki Tsuchihashi-Makaya and Hiroaki Chishaki and Masao Takemoto and Yasushi Mukai and Shujiro Inoue and Kenji Sunagawa",
year = "2012",
month = "11",
doi = "10.2459/JCM.0b013e3283585383",
language = "English",
volume = "13",
pages = "747--754",
journal = "Journal of Cardiovascular Medicine",
issn = "1558-2027",
publisher = "Lippincott Williams and Wilkins Ltd.",
number = "11",

}

TY - JOUR

T1 - Bepridil is effective and improves QOL in multidrug-resistant paroxysmal atrial fibrillation

AU - Shamoto, Atsushi

AU - Chishaki, Akiko

AU - Tsuchihashi-Makaya, Miyuki

AU - Chishaki, Hiroaki

AU - Takemoto, Masao

AU - Mukai, Yasushi

AU - Inoue, Shujiro

AU - Sunagawa, Kenji

PY - 2012/11

Y1 - 2012/11

N2 - OBJECTIVE: Efficacy and safety of long-term administration of bepridil as a rhythm and rate controller were comprehensively evaluated in patients with multidrug-resistant paroxysmal atrial fibrillation (PAF). METHODS: A retrospective survey from 1992 to 2006 was conducted on 62 multidrug-resistant PAF patients treated with bepridil from 480 consecutive PAF patients. In addition, a 5-year follow-up study was conducted on 28 of the 62 patients, being continued from 2006 to 2011. The efficacy of bepridil, improvement in symptoms including patients' quality of life (QOL), ECGs, hemodynamics, and its adverse effects were examined. RESULTS: In the retrospective survey, 127±44mg of bepridil was given for 21±18 months and 40.3% maintained sinus rhythm. Reductions in the frequency and the duration of each episode of PAF and improvement in symptoms were seen in 48.4, 50.0 and 93.5% of the 62 patients, respectively. Reversible torsades de pointes (TdP) occurred in two aged women. Bradycardia and hepatic dysfunction developed in one patient each. In the follow-up study, 100±20mg of bepridil was given. Sinus rhythm was maintained in 13 patients. Although the occurrences of PAF continued in 14 patients, their symptoms and QOL were improved. No adverse effects were noted in all 28 patients of the follow-up study. CONCLUSIONS: Bepridil was effective in rhythm control in 40% of PAF patients resistant to other antiarrhythmics. Even in those who had failed to maintain sinus rhythm, continued administration of low-dose bepridil improved their symptoms and QOL with few adverse effects. Bepridil is worth returning to use.

AB - OBJECTIVE: Efficacy and safety of long-term administration of bepridil as a rhythm and rate controller were comprehensively evaluated in patients with multidrug-resistant paroxysmal atrial fibrillation (PAF). METHODS: A retrospective survey from 1992 to 2006 was conducted on 62 multidrug-resistant PAF patients treated with bepridil from 480 consecutive PAF patients. In addition, a 5-year follow-up study was conducted on 28 of the 62 patients, being continued from 2006 to 2011. The efficacy of bepridil, improvement in symptoms including patients' quality of life (QOL), ECGs, hemodynamics, and its adverse effects were examined. RESULTS: In the retrospective survey, 127±44mg of bepridil was given for 21±18 months and 40.3% maintained sinus rhythm. Reductions in the frequency and the duration of each episode of PAF and improvement in symptoms were seen in 48.4, 50.0 and 93.5% of the 62 patients, respectively. Reversible torsades de pointes (TdP) occurred in two aged women. Bradycardia and hepatic dysfunction developed in one patient each. In the follow-up study, 100±20mg of bepridil was given. Sinus rhythm was maintained in 13 patients. Although the occurrences of PAF continued in 14 patients, their symptoms and QOL were improved. No adverse effects were noted in all 28 patients of the follow-up study. CONCLUSIONS: Bepridil was effective in rhythm control in 40% of PAF patients resistant to other antiarrhythmics. Even in those who had failed to maintain sinus rhythm, continued administration of low-dose bepridil improved their symptoms and QOL with few adverse effects. Bepridil is worth returning to use.

UR - http://www.scopus.com/inward/record.url?scp=84869879109&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84869879109&partnerID=8YFLogxK

U2 - 10.2459/JCM.0b013e3283585383

DO - 10.2459/JCM.0b013e3283585383

M3 - Article

VL - 13

SP - 747

EP - 754

JO - Journal of Cardiovascular Medicine

JF - Journal of Cardiovascular Medicine

SN - 1558-2027

IS - 11

ER -